In the late 2000s, many companies, particularly Big Pharma, exited the field of central nervous system (CNS) drug development and, particularly psychiatry. “Big Pharma exited the space because they were facing their patent cliff at the time and had to make some critical decisions about where to invest their resources,” said Emer Leahy, CEO of…
4 next-gen CNS drug development trends
The past couple of years have had a significant impact on CNS drug development, but it remains difficult to gauge how the field will evolve in the coming years. Many Big Pharma companies have AI initiatives, but most remain at a nascent stage. The pandemic has exacerbated the mental health crisis, leading to a surge…
The CNS drug development drum beat is getting louder
The late 1980s and the 1990s were something of a gold rush for pharmaceutical companies focused on CNS drug development — especially those developing psychiatric drugs. In 1988, Eli Lilly introduced the blockbuster SSRI Prozac (fluoxetine), then a new type of antidepressant. Big Pharma companies launched several SSRIs in the years that followed. By the…